Phase II Results For Yale’s Early Stage Ovarian Cancer Blood Test 99% Accurate

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced that Yale University has released the results of its Phase II study on a blood test to detect early stage ovarian cancer. Using six biomarkers, this blood test can discriminate between disease-free women and ovarian cancer patients (stage I-IV) with high specificity (99.4%) and sensitivity (95.3%). A Phase III trial is under way and should be completed in a few months.

More: continued here

Filed under: Blood on February 26th, 2008